Viewing Study NCT04481594



Ignite Creation Date: 2024-05-06 @ 2:58 PM
Last Modification Date: 2024-10-26 @ 1:40 PM
Study NCT ID: NCT04481594
Status: UNKNOWN
Last Update Posted: 2021-02-10
First Post: 2020-07-16

Brief Title: A Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of HPN-01 in Healthy Subjects
Sponsor: Hepanova Inc
Organization: Hepanova Inc

Study Overview

Official Title: A Randomized Double-Blind Placebo Controlled Sequential Parallel Group Single and Multiple Ascending Doses SADMAD Study Following Oral Administration in Healthy Subjects to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of HPN-01
Status: UNKNOWN
Status Verified Date: 2021-02
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study is a randomized double-blind placebo-controlled first-in-human study in which the safety tolerability pharmacokinetics and pharmacodynamics of orally administered HPN-01 will be evaluated in healthy subjects
Detailed Description: This study aims to obtain safety tolerability pharmacokinetic and pharmacodynamic data when HPN-01 is orally administered as single doses and as multiple doses to healthy subjects

The study will be conducted in 2 parts a single ascending dose SAD phase Part 1 and a multiple ascending dose MAD phase Part 2 One cohort of Part 1 will receive HPN-01 after a standard high fathigh calorie breakfast the fed condition to investigate the effect of food on the pharmacokinetics of HPN-01

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None